EAM
DRUG

Eventide Asset Management’s Bright Minds Biosciences DRUG Stock Holding History

Eventide Asset Management’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.13M Hold
130,013
– – 0.12% 157
2026
Q1 		$9.49M Buy
130,013
+27,000
+26% +$2.17M 0.16% 142
2025
Q4 		$8.04M Buy
+103,013
New +$6.88M 0.13% 152

Other funds holding DRUG

JT
Jupiter Topco New York $245B AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Eventide Asset Management's DRUG Position: Q2 2026 in Review

Eventide Asset Management held its Bright Minds Biosciences (DRUG) position steady in Q2 2026 at 130,013 shares worth $9.13M. The position accounts for 0.12% of the portfolio, ranked #157.

Eventide Asset Management first reported a position in DRUG in Q4 2025 and has held it in 3 quarters since. The position peaked at $9.49M in Q1 2026. 100 funds tracked by Wall St. Rank hold DRUG as of Q2 2026.

  • Eventide Asset Management held 130,013 shares of Bright Minds Biosciences worth $9.13M as of Q2 2026.
  • Eventide Asset Management left its Bright Minds Biosciences share count unchanged in Q2 2026.
  • Bright Minds Biosciences made up 0.12% of Eventide Asset Management's portfolio in Q2 2026, its #157 holding.
  • Eventide Asset Management first reported a position in Bright Minds Biosciences in Q4 2025 and has held it in 3 quarters since.
  • Eventide Asset Management's Bright Minds Biosciences position peaked at $9.49M in Q1 2026.
  • 100 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q2 2026.

Based on Eventide Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.